Share on StockTwits
 

Analysts at Roth Capital increased their target price on shares of Chelsea Therapeutics International (NASDAQ:CHTP) to $7.00 in a research report issued to clients and investors on Friday, StockRatingsNetwork.com reports. Roth Capital’s price target points to a potential upside of 47.06% from the company’s current price.

A number of other firms have also recently commented on CHTP. Analysts at Deutsche Bank raised their price target on shares of Chelsea Therapeutics International from $4.00 to $5.00 in a research note to investors on Wednesday. They now have a “hold” rating on the stock. Separately, analysts at Ladenburg Thalmann raised their price target on shares of Chelsea Therapeutics International to $7.00 in a research note to investors on Wednesday. Finally, analysts at Needham & Company raised their price target on shares of Chelsea Therapeutics International from $4.00 to $8.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $7.00.

Shares of Chelsea Therapeutics International (NASDAQ:CHTP) traded up 1.28% during mid-day trading on Friday, hitting $4.76. 9,159,931 shares of the company’s stock traded hands. Chelsea Therapeutics International has a one year low of $0.76 and a one year high of $5.78. The stock’s 50-day moving average is $3.80 and its 200-day moving average is $3.16. The company’s market cap is $336.9 million. Chelsea Therapeutics International also was the target of unusually large options trading on Wednesday. Investors bought 66,874 call options on the stock. This is an increase of 574% compared to the typical daily volume of 9,921 call options.

Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.